Get to know our clinical trials

Clinical trial of Xmab24306 in monotherapy and in combination with Atezolizumab in patients with locally advanced or metastatic solid tumors.

THE OBJECTIVE OF THIS STUDY IS TO EVALUATE XMAB24306 AT DIFFERENT DOSES TO DETERMINE IF IT IS SAFE AND TO LEARN HOW YOUR BODY PROCESSES THE DRUG.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE IA/IB, OPEN-LABEL, MULTICENTER, GLOBAL, DOSE-ESCALATION, PHASE IA/IB STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF XMAB24306 IN MONOTHERAPY AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS. IMMUNOTHERAPY
  • Code EudraCT: 2019-003986-16
  • Protocol number: GO41596
  • Promoter: Genentech, Inc.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.